Posted: 14 September 2023
Closes: 2 October 2023
Cyban is a Melbourne-based company developing a medical device that delivers revolutionary non-invasive, continuous monitoring of brain oxygen, intracranial pressure and perfusion for patients with life-threatening head injuries.
Your brief is to achieve commercialisation by promoting the monitor to key opinion leaders, in order to implement Cyban’s global launch strategy.
With proven team leadership, expertise in medical device sales and marketing, you are skilled in relationship building within the US hospital market. Your capital raising achievements have been developed in innovative, growth-stage companies.
To apply: Please view the Position Profile below and click on “Apply for Job” at the bottom of the page, attaching a tailored CV (Word version) by 5pm Monday 2 October, or call Jeremy Wurm on 0419 529 525 or Dr Rachel Cameron on 0476 498 982, to enquire confidentially.
Cyban is developing a class II medical device that provides non-invasive, continuous reporting of brain oxygen, intracranial pressure and perfusion for unconscious and intubated patients with existing, or at risk of, brain injury – the Brain Pulse Monitor. Initial launch will occur in intensive care units followed by operating theatres, emergency departments and first responders. The Brain Pulse Monitor output correlates with the current invasive “gold” standard of care, enabling earlier detection of symptom deterioration, to inform timely clinician decision making. This will lead to improved patient outcomes at lower cost for hospitals and the healthcare system.
Cyban’s technology provides a radical step forward in patient care. When oxygen flow to the brain is depleted, there are serious consequences to brain function – brain cells die within 2 minutes if starved of oxygen. The current standard of care for identifying brain injury in high risk patients who are unconscious and intubated is physical examination of the pupil (does not measure brain oxygen or intracranial pressure and identifies a problem after brain damage has occurred); brain scans (identifies a problem after brain damage has occurred and are expensive); or drilling a hole in the skull to insert an invasive monitoring probe (10% risk of further brain injury, 3% risk of infection, delay between decision to implant and reporting, with high cost).
Cyban has completed and published studies in animals and patients, including a pivotal trial at Duke University, in preparation for an FDA submission in December 2023. Once FDA cleared, Cyban will move to soft launch in the US in 2024 and full marketing, distribution, and sales launch in the US in 2025.
We are seeking a leader (CEO) who will, amongst other things, bring experience gained in:
Medical device companies with products and technology targeting hospitals. Experience in product management, marketing, and sales, with P&L responsibility in a medtech company. They will have experience selling devices used in critical care, intensive care units, neurology critical care, operating theatres, or emergency departments;
Early-stage companies. They must have experience of working with early stage medtech companies, developing the market for a new product in conjunction with key opinion leaders and growing a new product from pre-sales to revenue generation;
US markets. They should have experience of working in the US and successfully launching new medtech products within the top 10 US Centre of Excellence hospitals;
Capital raising. It is preferable that they have experience leading a company through capital raisings (private or IPO) and ideally have listed markets experience;
Team Leadership: Developing a team to execute on research, product development, marketing, distribution, and sales strategies in the global medical device market.
The candidate may be a current or former CEO or executive with a background in Medtech Marketing and Sales, or Product Management.
It is preferred that they are based in Melbourne (or prepared to relocate).
In terms of approach, behaviour and style, the candidate will need to demonstrate:
This role offers the opportunity to build a company that supports clinicians’ needs, and makes a high value difference to the health and wellbeing of people at a critical time of their lives. Cyban has a significant technology difference that will enable it to be a global Australian medtech success story that delivers outsized financial returns to its shareholders.